HighGravityDataCurrent guidance
28 items
Hologic
Guidance from Hologic’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 30, 2025
Data checked
Jan 29, 2026
What changed in the Jul 30, 2025 release
Each item compared with the same item in the previous release (Nov 3, 2025). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Non-GAAP earnings per share growth relative to revenue | for Q4 FY2025 | — | “will grow faster than revenue” | Filing ↗ |
| New | Organic, constant currency revenue growth excluding COVID | for Q4 FY2025 | — | “mid-single-digit growth” | Filing ↗ |
| New | Organic, constant currency revenue growth excluding COVID | for Q4 FY2025 | — | “mid-single-digit growth” | Filing ↗ |
| Narrowed | Revenue | for FY2025 | “$4,050 - $4,100” | “$4,081 - $4,091” | Filing ↗ |
| New | Revenue | for Q4 FY2025 | — | “$1,030 - $1,040” | Filing ↗ |
| Narrowed | Revenue Constant Currency % Increase (Decrease) | for FY2025 | “0.8% to 2.1%” | “1.1% to 1.4%” | Filing ↗ |
| New | Revenue Constant Currency % Increase (Decrease) | for Q4 FY2025 | — | “3.7% to 4.7%” | Filing ↗ |
| Raised | Revenue Organic % Increase (Decrease) | for FY2025 | “(0.7%) to 0.5%” | “(0.5%) to (0.2%)” | Filing ↗ |
| New | Revenue Organic % Increase (Decrease) | for Q4 FY2025 | — | “2.7% to 3.7%” | Filing ↗ |
| Narrowed | Revenue Organic excluding COVID-19 % Increase (Decrease) | for FY2025 | “0.3% to 1.6%” | “0.6% to 0.8%” | Filing ↗ |
| New | Revenue Organic excluding COVID-19 % Increase (Decrease) | for Q4 FY2025 | — | “3.9% to 5.0%” | Filing ↗ |
| Narrowed | Revenue Reported % Increase (Decrease) | for FY2025 | “0.5% to 1.7%” | “1.3% to 1.5%” | Filing ↗ |
| New | Revenue Reported % Increase (Decrease) | for Q4 FY2025 | — | “4.3% to 5.3%” | Filing ↗ |
| Raised | GAAP EPS | for FY2025 | “$2.47 - $2.57” | “$2.56 - $2.59” | Filing ↗ |
| New | GAAP EPS | for Q4 FY2025 | — | “$0.90 - $0.93” | Filing ↗ |
| Raised | GAAP EPS Reported % Increase (Decrease) | for FY2025 | “(25.6%) to (22.6%)” | “(22.9%) to (22.0%)” | Filing ↗ |
| New | GAAP EPS, Reported % Increase (Decrease) | for Q4 FY2025 | — | “18.4% to 22.4%” | Filing ↗ |
| Raised | Non-GAAP EPS | for FY2025 | “$4.15 - $4.25” | “$4.23 - $4.26” | Filing ↗ |
| New | Non-GAAP EPS | for Q4 FY2025 | — | “$1.09 - $1.12” | Filing ↗ |
| Raised | Non-GAAP EPS Reported % Increase (Decrease) | for FY2025 | “1.7% to 4.2%” | “3.7% to 4.4%” | Filing ↗ |
| New | Non-GAAP EPS, Reported % Increase (Decrease) | for Q4 FY2025 | — | “7.9% to 10.9%” | Filing ↗ |
| Reiterated | Diluted shares outstanding | for FY2025 | “approximately 228 million” | “approximately 228 million” | Filing ↗ |
| Reiterated | Diluted shares outstanding assumption | for FY2025 | “approximately 228 million” | “approximately 228 million” | Filing ↗ |
| Reiterated | Non-GAAP tax rate | for FY2025 | “approximately 19.25%” | “approximately 19.25%” | Filing ↗ |
| Reiterated | Non-GAAP tax rate assumption | for FY2025 | “approximately 19.25%” | “approximately 19.25%” | Filing ↗ |
Show 1 item not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Diluted shares outstanding ( basis) | for FY2025 | “approximately 235 million” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Non-GAAP earnings per share growth relative to revenue | “will grow faster than revenue” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Organic, constant currency revenue growth excluding COVID | “mid-single-digit growth” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Organic, constant currency revenue growth excluding COVID | “mid-single-digit growth” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Revenue | “$4,081 - $4,091” | for FY2025 | GAAP-tied | Nov 4, 2024 | 3 | Filing ↗ |
| Revenue | “$1,030 - $1,040” | for Q4 FY2025 | GAAP-tied | Jul 30, 2025 | 1 | Filing ↗ |
| Revenue Constant Currency % Increase (Decrease) | “1.1% to 1.4%” | for FY2025 | Company-defined | Nov 4, 2024 | 3 | Filing ↗ |
| Revenue Constant Currency % Increase (Decrease) | “3.7% to 4.7%” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Revenue Organic % Increase (Decrease) | “(0.5%) to (0.2%)” | for FY2025 | Company-defined | Nov 4, 2024 | 3 | Filing ↗ |
| Revenue Organic % Increase (Decrease) | “2.7% to 3.7%” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | “0.6% to 0.8%” | for FY2025 | Company-defined | Nov 4, 2024 | 3 | Filing ↗ |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | “3.9% to 5.0%” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Revenue Reported % Increase (Decrease) | “1.3% to 1.5%” | for FY2025 | GAAP-tied | Nov 4, 2024 | 3 | Filing ↗ |
| Revenue Reported % Increase (Decrease) | “4.3% to 5.3%” | for Q4 FY2025 | GAAP-tied | Jul 30, 2025 | 1 | Filing ↗ |
| GAAP EPS | “$2.56 - $2.59” | for FY2025 | GAAP-tied | Nov 4, 2024 | 3 | Filing ↗ |
| GAAP EPS | “$0.90 - $0.93” | for Q4 FY2025 | GAAP-tied | Jul 30, 2025 | 1 | Filing ↗ |
| GAAP EPS Reported % Increase (Decrease) | “(22.9%) to (22.0%)” | for FY2025 | GAAP-tied | Nov 4, 2024 | 3 | Filing ↗ |
| GAAP EPS, Reported % Increase (Decrease) | “18.4% to 22.4%” | for Q4 FY2025 | GAAP-tied | Jul 30, 2025 | 1 | Filing ↗ |
| Non-GAAP EPS | “$4.23 - $4.26” | for FY2025 | Company-defined | Nov 4, 2024 | 3 | Filing ↗ |
| Non-GAAP EPS | “$1.09 - $1.12” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Non-GAAP EPS Reported % Increase (Decrease) | “3.7% to 4.4%” | for FY2025 | Company-defined | Nov 4, 2024 | 3 | Filing ↗ |
| Non-GAAP EPS, Reported % Increase (Decrease) | “7.9% to 10.9%” | for Q4 FY2025 | Company-defined | Jul 30, 2025 | 1 | Filing ↗ |
| Anticipated closing of Gynesonics acquisition | “first half of calendar year 2025” | for FY2025 | Company-defined | Nov 4, 2024 | 1 | Filing ↗ |
| Diluted shares outstanding | “approximately 228 million” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
| Diluted shares outstanding ( basis) | “approximately 235 million” | for FY2025 | Company-defined | Nov 4, 2024 | 1 | Filing ↗ |
| Diluted shares outstanding assumption | “approximately 228 million” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
| Non-GAAP tax rate | “approximately 19.25%” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
| Non-GAAP tax rate ( basis) | “approximately 19.5%” | for FY2025 | Company-defined | Nov 4, 2024 | 1 | Filing ↗ |
| Non-GAAP tax rate assumption | “approximately 19.25%” | for FY2025 | Company-defined | May 1, 2025 | 2 | Filing ↗ |
How one item moved
Revenue, for FY2025 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2025 | FY2024 |
|---|---|---|
| Current revenue midpoint | — | 1 statement |
| Non-GAAP earnings per share growth relative to revenue | 1 statement | — |
| Organic, constant currency revenue growth excluding COVID | 2 statements | — |
| Revenue | 6 statements | 4 statements |
| Revenue Constant Currency % Increase (Decrease) | 6 statements | 4 statements |
The full record for Hologic and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jan 29, 2026 | FY2026 Q1 | 0001140361-26-002796 | 0 | Open filing ↗ |
| Nov 3, 2025 | FY2025 Q4 | 0001140361-25-040182 | 0 | Open filing ↗ |
| Jul 30, 2025 | FY2025 Q3 | 0001140361-25-028008 | 25 | Open filing ↗ |
| May 1, 2025 | FY2025 Q2 | 0001140361-25-016906 | 22 | Open filing ↗ |
| Jan 12, 2025 | FY2025 Q1 | 0001140361-25-000881 | 0 | Open filing ↗ |
| Nov 4, 2024 | FY2024 Q4 | 0001140361-24-045107 | 24 | Open filing ↗ |
| Jul 29, 2024 | FY2024 Q3 | 0001140361-24-034651 | 20 | Open filing ↗ |
| May 2, 2024 | FY2024 Q2 | 0001140361-24-023989 | 24 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error